A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
Public ClinicalTrials.gov record NCT02773524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Study identification
- NCT ID
- NCT02773524
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Australasian Gastro-Intestinal Trials Group
- Network
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Interventions
- Placebo Other
- Regorafenib Drug
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2016
- Primary completion
- Dec 31, 2021
- Completion
- Nov 30, 2022
- Last update posted
- Jan 12, 2022
2016 – 2022
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85054 | — |
| USC Norris | Los Angeles | California | 90001 | — |
| Carle Cancer Center NCI Community Oncology Research Program | Urbana | Illinois | 61801 | — |
| Bon Secours Cancer Institute | Midlothian | Virginia | 76065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02773524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 12, 2022 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02773524 live on ClinicalTrials.gov.